ASML's First-Quarter Report to Set Tone Amid Regulatory and Revenue Crosscurrents

ASML's Q1 2026 results test its 25% stock rally amid U.S. MATCH Act threat to China sales, a critical order backlog, and strong EUV system growth.

Investors in ASML Holding NV are bracing for a pivotal week, with the chip equipment giant's first-quarter 2026 results due on Tuesday, April 15. The report arrives after a period of significant volatility, driven by geopolitical tensions and a sustained share buyback program, and will serve as a crucial test for the stock's 25 percent rally since the start of the year.

The most immediate pressure point is a new piece of U.S. legislation. The bipartisan MATCH Act, introduced in Congress, aims to cut off Chinese semiconductor manufacturers, including SMIC, Hua Hong, Huawei, CXMT, and YMTC, from accessing Western chipmaking tools. Unlike prior restrictions, this bill would also encompass older deep ultraviolet (DUV) lithography systems, which China has been permitted to buy until now. An analyst from Quilter Cheviot estimates these machines account for roughly 10 to 15 percent of ASML's total sales, with about half of that coming from China. The potential net impact could be a revenue hit of approximately five percent.

This regulatory threat looms over ASML's strategic shift in a key market. China represented the company's largest single market in 2025, contributing 33 percent of total sales. Management already anticipates this share normalizing to around 20 percent in 2026, and the MATCH Act could accelerate that decline. The legislation, however, remains in an early stage and must complete the full congressional process.

Against this uncertainty, ASML's operational performance and order book will be under intense scrutiny. The company's own guidance for Q1 2026 forecasts net sales between €8.2 billion and €8.9 billion, with a gross margin of 51 to 53 percent. This represents a noticeable dip from the 54 percent margin a year earlier, attributed to product mix and softer service revenue. Analysts, on average, project revenue growth of 14 to 15 percent and earnings per share growth of 13 percent for the quarter.

More critical than the top-line figure will be the conversion rate of ASML's massive order backlog, which stood at €38.8 billion at the end of 2025. Investors are keenly focused on how efficiently the company can turn these commitments into recognized sales. Options markets are pricing in a share price move of around five percent on earnings day. CEO Christophe Fouquet and CFO Roger Dassen will host an investor call at 15:00 CET on April 15 to discuss the results.

Longer-term growth drivers remain robust, particularly in the cutting-edge extreme ultraviolet (EUV) segment. EUV revenue surged 39 percent in 2025, and more than half of new bookings are for EUV systems. Progress continues with the next-generation High-NA EUV system, the TWINSCAN EXE:5200B. Intel has completed acceptance tests, while SK Hynix has already installed the tool in its DRAM fab. Fouquet expects mass production to begin in 2027 and 2028. The company's long-term targets through 2030 are unchanged, aiming for annual revenue of €44 billion to €60 billion with gross margins between 56 and 60 percent.

Concurrently, ASML continues to return capital to shareholders. Between March 30 and April 3, the company repurchased nearly 88,000 shares for about €100 million as part of a program running through 2028 with a total volume of up to €12 billion. Following the earnings release, the annual general meeting in Veldhoven on April 22 will see shareholders vote on several items. These include the approval of the 2025 financial statements, the appointment of Marco Pieters as the new Chief Technology Officer, and the re-appointment of CFO Roger Dassen for a four-year term. A final dividend of €2.70 per share, a 17 percent increase from the prior year, is also on the agenda.

The average analyst price target for ASML shares sits around €1,482, implying an upside of roughly 18 percent from current levels. Tuesday's quarterly report will provide the first concrete data of the year to assess whether that optimism is warranted amidst the evolving regulatory landscape and shifting market dynamics.